Barclays Maintains Overweight on Kymera Therapeutics, Raises Price Target to $139
Barclays analyst Eliana Merle maintains Kymera Therapeutics (NASDAQ:KYMR) with a Overweight and raises the price target from $133 to $139.
Read original at benzingaStocks · News reference
Wells Fargo Maintains Overweight on Kymera Therapeutics, Raises Price Target to $151
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 27, 2026, 1:44 PM
- Checked
- Aug 27, 2026, 1:44 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
8-K filing — Kymera Therapeutics, Inc. (KYMR)
Filed: 2026-08-05 AccNo: 0001193125-26-333834 Size: 392 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgarKymera Therapeutics Q2 EPS $(0.62) Beats $(0.72) Estimate, Sales $65.000M Beat $31.165M Estimate
Kymera Therapeutics (NASDAQ:KYMR) reported quarterly losses of $(0.62) per share which beat the analyst consensus estimate of $(0.72) by 13.89 percent. This is a 34.74 percent increase over losses of $(0.95) per share
Read original at benzinga